Publication: Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR®) for the treatment of advanced HIV-infected patients: A 24-week study
Issued Date
2004-07-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-4444297218
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.87, No.7 (2004), 760-767
Suggested Citation
Thanomsak Anekthananon, Winai Ratanasuwan, Wichai Techasathit, Areeaue Sonjai, Surapol Suwanagool Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR®) for the treatment of advanced HIV-infected patients: A 24-week study. Journal of the Medical Association of Thailand. Vol.87, No.7 (2004), 760-767. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/21603
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR®) for the treatment of advanced HIV-infected patients: A 24-week study
Other Contributor(s)
Abstract
Objective: To determine the efficacy and safety of the fixed-dose combination of stavudine (d4T), lamivudine (3TC) and nevirapine (NVP) in the treatment of antiretroviral naïve HIV-infected Thai adults. Patients And Method: An open-label, single arm trial was conducted. Baseline clinical assessment and blood test was done on 101 antiretroviral naïve HIV-infected patients, who then received a fixed dose combination of d4T, 3TC and NVP (GPO-VIR®, Thai Government Pharmaceutical Organization, Bangkok, Thailand). Nevirapine was given as 200 mg once daily for the first 2 weeks. The patients were followed up at 2, 4, 8, 12 and 24 weeks. A CD4 cell count and HIV-RNA assay were done at 12 and 24 weeks. Results: One hundred and one patients were enrolled. The mean baseline CD4 cell count and mean HIV RNA were 58.7 (57.7) cells/mm3 and 5.3 (0.5) log10 copies/mL respectively. At week 24th, the mean decrease in log HIV RNA was 3.6 (0.7) log10 copies/mL [P < 0.001; 95% confidence interval (CI), 2.70-3.03]. Eighty one (80.2%) patients had HIV RNA < 400 copies/mL by intention-to-treat analysis (ITT) and 97.6% had HIV RNA < 400 copies/mL by on-treatment analysis (OT). Sixteen (84.2%) patients with baseline HIV RNA ≤ 100,000 copies/mL and 65 (82.3%) patients with baseline HIV RNA > 100,000 copies/mL had viral load < 400 copies/mL by ITT (P = 0.842; 95% CI, -20.9%-16.2%). Sixteen (94.1%) patients with baseline HIV RNA ≤ 100,000 copies/mL and 65 (98.5%) patients with baseline HIV RNA > 100,000 copies/mL had viral load < 400 copies/mL by OT (P = 0.295; 95% CI, -25.5%-3.8%). The mean CD4 cell count at week 24 was 155.1 (89.0) cells/mm3s (range 13-402). The mean increase in CD4 cell count from baseline was 96.5 (63.5) cells/mm3 (P < 0.001). A total of 12% of the patients receiving d4T + 3TC + NVP developed skin rashes. Grade 3 or 4 hepatotoxicity was recognized in 7% of the patients. Conclusion: Fixed-dose combination of d4T + 3TC + NVP (GPO-VIR®) is safe, well tolerated and effective in increasing CD4 cell counts and suppression of HIV RNA at 24 weeks in advanced HIV-infected patients in Thailand.